Duval Fabrice, Erb Alexis, Mokrani Marie-Claude, Weiss Thomas, Carcangiu Roberta
Pôle 8/9 Psychiatry APF2R Centre Hospitalier Rouffach France.
Psychiatr Res Clin Pract. 2021 May 19;3(4):146-152. doi: 10.1176/appi.prcp.20210010. eCollection 2021 Winter.
We examined whether the anti-saccade task (AST) performance after the first methylphenidate (MPH) dose could be associated with subsequent clinical outcome in adults with attention-deficit/hyperactivity disorder (ADHD).
Ninety-seven drug-naive DSM-5 ADHD adults participated in this study. The AST parameters were measured at baseline, after the first MPH-dose (10 mg orally), and 6 months after chronic MPH treatment. Results were compared with those of 50 healthy control (HC) subjects.
At baseline, ADHDs showed longer saccadic reaction times and more direction errors than HCs (both < 0.00001). Acute and chronic MPH administration resulted in normalization of the AST performances. Multivariate regression analysis after adjusting for age, sex, weight, and severity of symptoms at baseline, revealed that a low percentage of direction errors after the first MPH-dose (i.e., ≤10%) could predict remission at month 6 (OR: 5.84; 95% CI: 2.00-17.11; = 0.001).
Our findings indicate that: (1) impairments of motor planning and response inhibition in adults with ADHD are improved with MPH, and (2) a low direction error percentage after the first MPH-dose may be an independent predictor of remission.ClinicalTrials.gov identifier: NCT03411434.
我们研究了首次服用哌甲酯（MPH）后抗扫视任务（AST）的表现是否与成人注意力缺陷多动障碍（ADHD）的后续临床结果相关。
97名未服用过药物的DSM-5 ADHD成人参与了本研究。在基线、首次服用MPH剂量（口服10毫克）后以及MPH长期治疗6个月后测量AST参数。将结果与50名健康对照（HC）受试者的结果进行比较。
在基线时，ADHD患者的扫视反应时间比HC患者更长，方向错误更多（均P<0.00001）。急性和慢性MPH给药使AST表现恢复正常。在对年龄、性别、体重和基线症状严重程度进行调整后的多变量回归分析显示，首次服用MPH剂量后方向错误的低百分比（即≤10%）可预测第6个月的缓解情况（OR：5.84；95%CI：2.00-17.11；P=0.001）。
我们的研究结果表明：（1）MPH可改善ADHD成人的运动计划和反应抑制障碍，（2）首次服用MPH剂量后低方向错误百分比可能是缓解的独立预测指标。ClinicalTrials.gov标识符：NCT03411434。
